Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 19/20 | 0.63 |
| ▸ | DHFR | P00374 | 2/20 | 0.63 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.63 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.63 |
| ▸ | GART | P22102 | 1/20 | 0.63 |
| ▸ | ATIC | P31939 | 1/20 | 0.63 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.63 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.63 |
| ▸ | FRK | P42685 | 1/20 | 0.63 |
| ▸ | SLC46A1 | Q96NT5 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2260428 | 0.89 | TYMS (0.69) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL18551642 | 0.89 | TYMS (0.64) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL25476851 | 0.89 | TYMS (0.64) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL8855177 | 0.89 | TYMS (0.61) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL13524779 | 0.89 | TYMS (0.67) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL2260030 | 0.88 | TYMS (0.67) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL2260032 | 0.87 | TYMS (0.68) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL14612488 | 0.86 | TYMS (0.67) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL12238856 | 0.85 | TYMS (0.57) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL16569503 | 0.83 | TYMS (0.58) | TYMSDHFRFOLR2FOLR1GART |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9814777-B2 | Targeting lipids | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-11-14 | — | — | US | disclosed |
| US-9814777-B2 | Targeting lipids | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-11-14 | — | — | US | disclosed |
| EP-3156077-A1 | TARGETING LIPIDS | Arbutus Biopharma Corporation (CA) | 2017-04-19 | — | — | EP | disclosed |
| EP-2231195-B1 | TARGETING LIPIDS | ARBUTUS BIOPHARMA CORP (CA) | 2017-03-29 | — | — | EP | disclosed |
| US-20160375137-A9 | TARGETING LIPIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-12-29 | — | — | US | disclosed |
| US-20160214987-A1 | METHOD FOR PREPARING AN INTERMEDIATE FOR PRODUCING HIGH-PURITY PEMETREXED AND METHOD FOR PRODUCING HIGH-PURITY PEMETREXED USING THE INTERMEDIATE | SAMYANG BIOPHARMACEUTICALS CORPORATION (KR) | 2016-07-28 | — | — | US | disclosed |
| EP-1957497-B1 | PROCESSES FOR PREPARING INTERMEDIATES OF PEMETREXED | SICOR INC (US) | 2015-09-30 | — | — | EP | disclosed |
| US-20150259348-A1 | PROCESS FOR PREPARING PEMETREXED DI POTASSIUM AND ITS HYDRATES | SHILPA MEDICARE LIMITED (IN) | 2015-09-17 | — | — | US | disclosed |
| US-20140179761-A1 | TARGETING LIPIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-06-26 | — | — | US | disclosed |
| US-20140179761-A1 | TARGETING LIPIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-06-26 | — | — | US | disclosed |
| US-8680319-B2 | Method for producing antifolate agents having glutamic acid part in their structure | KOCAK FARMA ILAC VE KIMYA SAN. A.S (TR) | 2014-03-25 | — | — | US | disclosed |
| US-20130253192-A1 | Method for producing antifolate agents having glutamic acid part in their structure | KOCAK FARMA ILAC VE KIMYA SAN. A.S (TR) | 2013-09-26 | — | — | US | disclosed |
| US-20090247608-A1 | Targeting Lipids | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009082607-A2 | TARGETING LIPIDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247608-A1 | Targeting Lipids | LY96, ABHD10, APOB | TYMS 2326/4885DHFR 1267/4885FOLR2 651/4885 |
| US-20160214987-A1 | METHOD FOR PREPARING AN INTERMEDIATE FOR PRODUCING HIGH-PURITY PEMETREXED AND METHOD FOR PRODUCING HIGH-PURITY PEMETREXED USING THE INTERMEDIATE | SAMHD1, IMPDH1, DCTD | TYMS 13/4885DHFR 15/4885FOLR2 105/4885 |
| US-20130253192-A1 | Method for producing antifolate agents having glutamic acid part in their structure | GLUL, DHFR, FOLH1 | TYMS 286/4885DHFR 2/4885FOLR2 16/4885 |
| US-20140179761-A1 | TARGETING LIPIDS | LY96, ABHD10, APOB | TYMS 2270/4885DHFR 1253/4885FOLR2 647/4885 |
| US-20150259348-A1 | PROCESS FOR PREPARING PEMETREXED DI POTASSIUM AND ITS HYDRATES | DPYD, KCNK5, KCNJ11 | TYMS 4/4885DHFR 62/4885FOLR2 255/4885 |
| US-20160375137-A9 | TARGETING LIPIDS | LY96, ABHD10, APOB | TYMS 2270/4885DHFR 1253/4885FOLR2 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.